Bimekizumab
- Generic Name
- Bimekizumab
- Brand Names
- Bimzelx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1418205-77-2
- Unique Ingredient Identifier
- 09495UIM6V
- Background
Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. It is the first IL-17 inhibitor to target both IL-17A and IL-17F. It has demonstrated superior efficacy as compared to another IL-17 inhibitor, secukinumab, as well as ustekinumab (an IL-12/23 ...
- Indication
Bimekizumab is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- UCB Biopharma S.P.R.L.
- Target Recruit Count
- 303
- Registration Number
- NCT02963506
- Locations
- 🇺🇸
As0008 027, Boston, Massachusetts, United States
🇧🇬As0008 154, Plovdiv, Bulgaria
🇷🇺As0008 601, Moscow, Russian Federation
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- UCB Biopharma S.P.R.L.
- Target Recruit Count
- 250
- Registration Number
- NCT02905006
- Locations
- 🇺🇸
Ps0010 736, Cleveland, Ohio, United States
🇺🇸Ps0010 733, Dallas, Texas, United States
🇺🇸Ps0010 709, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.